接受器官支持治疗的COVID-19患者结局:国际病毒感染与呼吸疾病通用研究登记
该研究为多中心国际横断面观察性登记,纳入2020年2月15日至11月30日16国168家医院20,608例住院COVID-19成人患者。主要结局为院内死亡。无器官支持者死亡率8.2%,有创机械通气者49.8%,仅机械通气者40.8%,机械通气联合血管活性药和新肾脏替代治疗者71.6%,ECMO者39%。校正患者特征后,机械通气患者院内死亡率医院间变异仍大(中位OR 1.69)。
要点
- 无器官支持者院内死亡率8.2%(n=15,001),有创机械通气者49.8%(n=5,005)。
- 仅接受有创机械通气者死亡率40.8%(n=1,749),联合血管活性药和新增肾脏替代治疗者71.6%(n=655)。
- 接受ECMO者院内死亡率39%(n=389)。
- 机械通气患者出院回家比例:仅机械通气者29.8%,联合血管活性药和肾脏替代者8.8%;>74岁机械通气者仅10.8%出院回家。
- 机械通气患者院内死亡率医院间变异大(中位OR 1.69),未被患者特征解释。
适用人群与场景
- 16国168家医院内住院的成人COVID-19患者(实验室确诊SARS-CoV-2感染),入院时间2020年2月15日至2020年11月30日。
- 纳入接受或不接受器官支持(机械通气、肾脏替代治疗、血管活性药、ECMO)的不同类型和组合的患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 主要终点院内死亡率:无器官支持者8.2%(n=15,001);有创机械通气者49.8%(n=5,005);仅机械通气者40.8%(n=1,749);机械通气+血管活性药+新肾脏替代治疗者71.6%(n=655);ECMO者39%(n=389)。
- 次要终点出院回家率:无器官支持者73.5%;仅机械通气者29.8%;机械通气+血管活性药+肾脏替代者8.8%;>74岁机械通气者10.8%。
- 机械通气患者中位住院时间17.1天(9.7-28天)。
- 校正年龄、种族/ ethnicity、性别和合并症后,机械通气患者院内死亡率医院间变异大(中位OR 1.69)。
证据类型、等级与局限
- 证据类型:多中心国际横断面观察性登记研究。
- 局限性:观察性设计,无法推断因果关系;原文未提及证据等级或推荐强度。
对床旁实践的改变
- 可依据年龄和器官支持类型向家属告知COVID-19预后:无器官支持者院内死亡率8.2%,有创机械通气者49.8%,联合血管活性药和肾脏替代者71.6%,ECMO者39%。
- 机械通气患者出院回家比例低(仅机械通气29.8%,联合血管活性药和肾脏替代8.8%),>74岁机械通气者仅10.8%,可用于出院规划沟通。
- 机械通气患者死亡率医院间变异大(中位OR 1.69),提示诊疗水平或资源配置差异可能影响结局,需进一步评估。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To describe the outcomes of hospitalized patients in a multicenter, international coronavirus disease 2019 registry.
DESIGN: Cross-sectional observational study including coronavirus disease 2019 patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection between February 15, 2020, and November 30, 2020, according to age and type of organ support therapies.
SETTING: About 168 hospitals in 16 countries within the Society of Critical Care Medicine's Discovery Viral Infection and Respiratory Illness University Study coronavirus disease 2019 registry.
PATIENTS: Adult hospitalized coronavirus disease 2019 patients who did and did not require various types and combinations of organ support (mechanical ventilation, renal replacement therapy, vasopressors, and extracorporeal membrane oxygenation).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Primary outcome was hospital mortality. Secondary outcomes were discharge home with or without assistance and hospital length of stay. Risk-adjusted variation in hospital mortality for patients receiving invasive mechanical ventilation was assessed by using multilevel models with hospitals as a random effect, adjusted for age, race/ethnicity, sex, and comorbidities. Among 20,608 patients with coronavirus disease 2019, the mean (± sd) age was 60.5 (±17), 11,1887 (54.3%) were men, 8,745 (42.4%) were admitted to the ICU, and 3,906 (19%) died in the hospital. Hospital mortality was 8.2% for patients receiving no organ support (n = 15,001). The most common organ support therapy was invasive mechanical ventilation (n = 5,005; 24.3%), with a hospital mortality of 49.8%. Mortality ranged from 40.8% among patients receiving only invasive mechanical ventilation (n =1,749) to 71.6% for patients receiving invasive mechanical ventilation, vasoactive drugs, and new renal replacement therapy (n = 655). Mortality was 39% for patients receiving extracorporeal membrane oxygenation (n = 389). Rates of discharge home ranged from 73.5% for patients who did not require organ support therapies to 29.8% for patients who only received invasive mechanical ventilation, and 8.8% for invasive mechanical ventilation, vasoactive drugs, and renal replacement; 10.8% of patients older than 74 years who received invasive mechanical ventilation were discharged home. Median hospital length of stay for patients on mechanical ventilation was 17.1 days (9.7-28 d). Adjusted interhospital variation in mortality among patients receiving invasive mechanical ventilation was large (median odds ratio 1.69).
CONCLUSIONS: Coronavirus disease 2019 prognosis varies by age and level of organ support. Interhospital variation in mortality of mechanically ventilated patients was not explained by patient characteristics and requires further evaluation.
参考来源
- Domecq JP, Lal A, Sheldrick CR, et al. Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry. Crit Care Med. 2021. PMID: 33555777. doi:10.1097/CCM.0000000000004879
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。